6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling

US8710048B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• James Sutton · Princeton Junction, US
• Marion Wiesmann · Emeryville, US
• Weibo Wang · Moraga, US
• Mika Lindvall · Emeryville, US
• Jiong Lan · Moraga, US
• Savithri Ramurthy · Walnut Creek, US
• Anu Sharma · Corona, US
• Elizabeth Mieuli · Redwood City, US
• Liana M. Klivansky · Oakland, US
• William Lenahan · San Leandro, US
• Susan Kaufman · Lafayette, US
• Hong Yang · Foster City, US
• Simon Ng · Walnut Creek, US
• Keith B. Pfister · Emeryville, US
• Allan S. Wagman · Belmont, US
• Victoria Sung · San Francisco, US
• Martin Sendzik · Belmont, US

Key dates

• Filing date: Apr 23, 2012
• Grant date: Apr 29, 2014
• Expiry date: Apr 23, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.